Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.99Last Year’s EPS
-0.8Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -26.38%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong initial sales of newly launched products and promising developments in the pipeline. While there are some uncertainties regarding market size and reimbursement, the overall outlook is optimistic due to financial stability and strategic advancements.Company Guidance
During Syndax Pharmaceuticals' first quarter 2025 earnings call, the company provided guidance on its recent commercial and clinical progress. Syndax reported $20 million in net revenue from the first full quarter of the Revuforj launch and $13.6 million from its joint launch of Niktimvo with Incyte, totaling $34 million in net sales. The company highlighted its robust pipeline, including ongoing pivotal trials like EVOLV-2, which is enrolling patients for the first frontline trial of a menin inhibitor. Syndax is well-funded with $602.1 million in cash and equivalents and expects to reach profitability with anticipated revenue contributions from Revuforj and Niktimvo. Additionally, Syndax is actively pursuing the inclusion of Revuforj in clinical guidelines and anticipates an expedited review process for its supplemental new drug application (sNDA) for Revuforj, seeking FDA approval for additional indications.Strong Product Launches
Syndax reported $20 million in Revuforj net revenue and $13.6 million in Niktimvo net revenue in the first quarter of 2025, indicating successful product launches and strong market reception.
Financial Stability
The company is well-funded with $602.1 million in cash and equivalents, and anticipates reaching profitability with current revenue streams.
Pipeline Progress
The initiation of the EVOLV-2 trial, a pivotal frontline trial of revumenib, marks significant advancement in the menin inhibitor program.
NCCN Guidelines Inclusion
Revuforj has been rapidly included in NCCN guidelines, with expectations for further inclusion in clinical guidelines for mutant mNPM1 AML treatment.
FDA sNDA Submission
A Supplemental New Drug Application for Revuforj has been submitted, seeking priority review for relapse or refractory mutant mNPM1 AML.
---
SNDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SNDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 05, 2025 | $13.57 | $10.64 | -21.59% |
| Mar 03, 2025 | $15.64 | $15.48 | -1.02% |
| Nov 05, 2024 | $19.69 | $21.35 | +8.43% |
| Aug 01, 2024 | $22.00 | $21.04 | -4.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Syndax Pharmaceuticals Inc (SNDX) report earnings?
Syndax Pharmaceuticals Inc (SNDX) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Syndax Pharmaceuticals Inc (SNDX) earnings time?
Syndax Pharmaceuticals Inc (SNDX) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNDX EPS forecast?
SNDX EPS forecast for the fiscal quarter 2025 (Q2) is -0.99.
---